Tharimmune Stock Forum

$Tharimmune (THAR.US)$ Reuters· just
Tharimmune: Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis

$Tharimmune (THAR.US)$
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Monday, 16th December at 8:00 am
BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 st...

$Tharimmune (THAR.US)$ what

$Tharimmune (THAR.US)$ This is interesting, good volumes observed on post market. Keep an eye on this.

$Crown Electrokinetics (CRKN.US)$ $Dermata Therapeutics (DRMA.US)$ $KORE Group (KORE.US)$ $Vivakor (VIVK.US)$ $Rent the Runway (RENT.US)$ $iCoreConnect (ICCT.US)$ $My Size (MYSZ.US)$ $Synaptogenix (SNPX.US)$ $Eupraxia Pharmaceuticals (EPRX.US)$ $Live Ventures (LIVE.US)$ $Worksport (WKSP.US)$ $Gaxos.ai (GXAI.US)$ $Tharimmune (THAR.US)$ $MEDIROM Healthcare Technologies (MRM.US)$
📊⚡️📊

$Tharimmune (THAR.US)$ offered at 2.03 and price hit 3.30 🤣🤣🤣

$Tharimmune (THAR.US)$
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Friday, 6th December at 4:15 pm
BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million throug...